Pete DeMuth
Chief Scientific Officer, Founding Scientist Elicio Therapeutics
Seminars
Thursday 18th September 2025
Amplifying mKRAS-Specific T cell Immunity for Treatment of MRD+ Pancreatic Cancer
11:30 am
- Targeting vaccine immunotherapy to lymph nodes with the AMP technology
- Development of ELI-002, an off-the-shelf therapeutic vaccine targeting mKRAS
- Clinical updates from AMPLIFY-201 and AMPLIFY-7P Phase 1/2 Trials
